よむ、つかう、まなぶ。
会議資料 (91 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00042.html |
| 出典情報 | 医薬・生活衛生局が実施する検討会 医療上の必要性の高い未承認薬・適応外薬検討会議（第68回 7／4）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
（公知申請への該当性に係る企業見解の様式）
要望番号；IV-168
32) Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a
prospective study of 20 patients. Leuk Lymphoma 2006; 47(2): 253-260.
33) NHS England. Clinical Commissioning Policy: Rituximab for cytopaenia complicating primary
immunodeficiency. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/07/
Rituximab-for-cytopaenia-complicating-primary-immunodeficiency.pdf [Cited 2024 Apr 23]
34) Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial
evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults
(the RAIHA study). Am J Hematol 2017; 92(1): 23-27.
35) Dierickx D, Verhoef G, Hoof AV, et al. Rituximab in auto-immune haemolytic anaemia and
immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med
2009; 266(5): 484-491.
36) Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of
childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358(9292): 1511-1513.
37) Bader-Meunier B, Aladjidi N, Bellmann F, et al. Haematologica 2007; 92(12): 1691-1694.
38) Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune
hemolytic anemia in children. Blood 2003; 101(10): 3857-3861.
39) Ducassou S, Leverger G, Fernandes H, et al. Benefits of rituximab as a second-line treatment for
autoimmune haemolytic anaemia in children: a prospective French cohort study. Br J Haematol
2017; 177(5): 751-758.
40) Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune
hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev 2015; 14(4): 304-313.
41) Cavallaro F, Barcellini W, Fattizzo B. Antibody based therapeutics for autoimmune hemolytic
anemia. Expert Opin Biol Ther 2023; 23(12): 1227-1237.
42) Cvetković Z, Pantić N, Cvetković M, et al. The Role of the Spleen and the Place of Splenectomy
in Autoimmune Hemolytic Anemia-A Review of Current Knowledge. Diagnostics (Basel). 2023;
13(18): 2891.
43) Bortolotti M, Barcellini W, Fattizzo B. Molecular pharmacology in complement-mediated
hemolytic disorders. Eur J Haematol 2023; 111(3): 326-336.
44) Berentsen S, Fattizzo B, Barcellini W. The choice of new treatments in autoimmune hemolytic
anemia: how to pick from the basket? Front Immunol 2023; 14:1180509.
45) Gelbenegger G, Berentsen S, Jilma B. Monoclonal antibodies for treatment of cold agglutinin
disease. Expert Opin Biol Ther 2023; 23(5): 395-406.
46) Goldman-Cecil medicine 27th ed volume 1. pp1087-1092.
47) Harrison's Principles of Internal Medicine 21st ed. pp786-788.
48) Williams Hematology 10th Edition. pp907-910.
49) Wintrobe’s Clinical Hematology 15th Edition volume 1. pp776-784.
50) Nathan and Oski's hematology and oncology of infancy and childhood 8th ed volume 1.
62
91 / 359
要望番号；IV-168
32) Schöllkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a
prospective study of 20 patients. Leuk Lymphoma 2006; 47(2): 253-260.
33) NHS England. Clinical Commissioning Policy: Rituximab for cytopaenia complicating primary
immunodeficiency. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/07/
Rituximab-for-cytopaenia-complicating-primary-immunodeficiency.pdf [Cited 2024 Apr 23]
34) Michel M, Terriou L, Roudot-Thoraval F, et al. A randomized and double-blind controlled trial
evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults
(the RAIHA study). Am J Hematol 2017; 92(1): 23-27.
35) Dierickx D, Verhoef G, Hoof AV, et al. Rituximab in auto-immune haemolytic anaemia and
immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med
2009; 266(5): 484-491.
36) Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of
childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358(9292): 1511-1513.
37) Bader-Meunier B, Aladjidi N, Bellmann F, et al. Haematologica 2007; 92(12): 1691-1694.
38) Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune
hemolytic anemia in children. Blood 2003; 101(10): 3857-3861.
39) Ducassou S, Leverger G, Fernandes H, et al. Benefits of rituximab as a second-line treatment for
autoimmune haemolytic anaemia in children: a prospective French cohort study. Br J Haematol
2017; 177(5): 751-758.
40) Reynaud Q, Durieu I, Dutertre M, et al. Efficacy and safety of rituximab in auto-immune
hemolytic anemia: A meta-analysis of 21 studies. Autoimmun Rev 2015; 14(4): 304-313.
41) Cavallaro F, Barcellini W, Fattizzo B. Antibody based therapeutics for autoimmune hemolytic
anemia. Expert Opin Biol Ther 2023; 23(12): 1227-1237.
42) Cvetković Z, Pantić N, Cvetković M, et al. The Role of the Spleen and the Place of Splenectomy
in Autoimmune Hemolytic Anemia-A Review of Current Knowledge. Diagnostics (Basel). 2023;
13(18): 2891.
43) Bortolotti M, Barcellini W, Fattizzo B. Molecular pharmacology in complement-mediated
hemolytic disorders. Eur J Haematol 2023; 111(3): 326-336.
44) Berentsen S, Fattizzo B, Barcellini W. The choice of new treatments in autoimmune hemolytic
anemia: how to pick from the basket? Front Immunol 2023; 14:1180509.
45) Gelbenegger G, Berentsen S, Jilma B. Monoclonal antibodies for treatment of cold agglutinin
disease. Expert Opin Biol Ther 2023; 23(5): 395-406.
46) Goldman-Cecil medicine 27th ed volume 1. pp1087-1092.
47) Harrison's Principles of Internal Medicine 21st ed. pp786-788.
48) Williams Hematology 10th Edition. pp907-910.
49) Wintrobe’s Clinical Hematology 15th Edition volume 1. pp776-784.
50) Nathan and Oski's hematology and oncology of infancy and childhood 8th ed volume 1.
62
91 / 359